Eugenii A Rabiner (E A Rabiner)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2013-2024
Publications (10 Years): 11

Top Topics

Alcohol Use Disorder

Positron Emission Tomography

Cognitive Impairment

Top Venues

Molecular psychiatry

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Clinical pharmacology and therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Khanum Ridler, Gaia Rizzo, Ethan S Burstein, Anton Forsberg Morén, Vladimir Stepanov, Christer Halldin, Eugenii A Rabiner
Imaging the 5-HT 2C receptor with PET: Evaluation of 5-HT 2C and 5-HT 2A affinity of pimavanserin in the primate brain. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2024)
Seth C Hopkins, Siriporn Toongsuwan, Taryn J Corriveau, Takao Watanabe, Yuki Tsushima, Takumi Asada, Robert Lew, Lei Shi, Vanessa Zann, Thomas J Snowden, Piet H van der Graaf, Borje Darpo, Graham E Searle, Eugenii A Rabiner, Ian Wilding, Steven T Szabo, Gerald R Galluppi, Kenneth S Koblan
Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain. Clinical pharmacology and therapeutics 116 (2) (2024)
Seth C Hopkins, Siriporn Toongsuwan, Taryn J Corriveau, Takao Watanabe, Yuki Tsushima, Takumi Asada, Robert Lew, Lei Shi, Vanessa Zann, Thomas J Snowden, Piet H van der Graaf, Borje Darpo, Graham E Searle, Eugenii A Rabiner, Ian Wilding, Steven T Szabo, Gerald R Galluppi, Kenneth S Koblan
Discovery and Model-Informed Drug Development of a Controlled-Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain. Clinical pharmacology and therapeutics (2024)
Matthew B Wall, Rebecca Harding, Rayyan Zafar, Eugenii A Rabiner, David John Nutt, David Erritzøe
Neuroimaging in psychedelic drug development: past, present, and future. Molecular psychiatry (2023)
Eugenii A Rabiner, Roger N Gunn
Estimation of target occupancy in repeated dosing design studies using positron emission tomography: Biases due to target upregulation. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (2023)
Eugenii A Rabiner, Tolga Uz, Ayla Mansur, Terry Brown, Grace Chen, Jingtao Wu, Joy Atienza, Adam J Schwarz, Wei Yin, Yvonne Lewis, Graham E Searle, Jeremy M T J Dennison, Jan Passchier, Roger N Gunn, Johannes Tauscher
Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2021)
Ellis Chika Onwordi, Thomas Whitehurst, Ayla Mansur, Ben K Statton, Alaine Berry, Marina Quinlan, Declan P O'Regan, Maria Rogdaki, Tiago Reis Marques, Eugenii A Rabiner, Roger N Gunn, Anthony Christopher Vernon, Sridhar Natesan, Oliver D Howes
The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational psychiatry 11 (1) (2021)
Valeria Calsolaro, Paul M Matthews, Cornelius K Donat, Nicholas R Livingston, Grazia D Femminella, Sandra Silva Guedes, Jim Myers, Zhen Fan, Robin J Tyacke, Ashwin V Venkataraman, Robert Perneczky, Roger Gunn, Eugenii A Rabiner, Steve Gentleman, Christine A Parker, Philip S Murphy, Paul B Wren, Rainer Hinz, Magdalena Sastre, David John Nutt, Paul Edison
Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11C-BU99008 PET and its relationship with amyloid load. Molecular psychiatry (2021)
Abhishekh Hulegar Ashok, Jim Myers, Tiago Reis Marques, Eugenii A Rabiner, Oliver D Howes
Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic Imaging. Nature communications 10 (1) (2019)
Samuel Turton, James Fm Myers, Inge Mick, Alessandro Colasanti, Ashwin Venkataraman, Claire Durant, Adam Waldman, Alan Brailsford, Mark C Parkin, Gemma Dawe, Eugenii A Rabiner, Roger N Gunn, Stafford L Lightman, David John Nutt, Anne Lingford-Hughes
Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. Molecular psychiatry 25 (8) (2018)
Inge Mick, Jim Myers, Anna C Ramos, Paul R A Stokes, David Erritzoe, Alessandro Colasanti, Roger N Gunn, Eugenii A Rabiner, Graham E Searle, Adam D Waldman, Mark C Parkin, Alan D Brailsford, José C F Galduróz, Henrietta Bowden-Jones, Luke Clark, David J Nutt, Anne R Lingford-Hughes
Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 41 (7) (2015)
Jean-Dominique Gallezot, Tracy Kloczynski, David Weinzimmer, David Labaree, Ming-Qiang Zheng, Keunpoong Lim, Eugenii A Rabiner, Khanum Ridler, Brian Pittman, Yiyun Huang, Richard E Carson, Evan D Morris, Kelly P Cosgrove
Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [(11)C]PHNO vs [(11)C]raclopride PET. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 39 (4) (2013)
M E Haahr, P M Fisher, C G Jensen, V G Frokjaer, B Mc Mahon, K Madsen, W F C Baaré, S Lehel, A Norremolle, Eugenii A Rabiner, G M Knudsen
Central 5-HT4 receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study. Molecular psychiatry 19 (4) (2013)